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Abstract.  Extracellular matrix proteins and their pro- 
teolytic products have been shown to modulate cell 
motility. We have found that certain tumor cells dis- 
play a chemotactic response to degradation products of 
the matrix protein elastin, and to an elastin-derived 
peptide, VGVAPG.  The hexapeptide VGVAPG is a par- 
ticularly potent chemotaxin for lung-colonizing Lewis 
lung carcinoma cells (line M27),  with 5 nM VGVAPG 
eliciting maximal chemotactic response when assayed 
in 48-microwell chemotaxis chambers.  Binding of the 
elastin-derived peptide to M27 cells was studied using 
a  tyrosinated analog (Y-VGVAPG) to allow iodination. 
Scatchard analysis of [125I]Y-VGVAPG binding to viable 
M27 tumor cells at both 37 and 4°C indicates the 
presence of a  single class of high affinity binding sites. 
The dissociation constant obtained from these studies 
(2.7)<  10  -9 M) is equivalent to the concentration of 
VGVAPG required for chemotactic activity. The recep- 
tor molecule was identified as an Mr 59,000  species by 
covalent cross-linking of the radiolabeled ligand to the 
M27 tumor cell surface and subsequent analysis of the 
cross-linked material by electrophoresis and size- 
exclusion high performance liquid chromatography. 
These results suggest that M27 tumor cell chemotaxis 
to VGVAPG is initiated by high affinity binding of the 
peptide to a distinct cell surface receptor. 
E 
LASTIN, an insoluble component of the extracellular 
matrix is best known for its ability to confer elasticity 
to extensible tissues such as the lung, arteries, skin, 
and elastic cartilage (6, 20). Elastin and elastin sequences in- 
teract with a variety of cell types to modulate cellular be- 
havior.  Insoluble elastin, for example, has been shown to 
mediate cell adhesion of monocytes, fibroblasts, and tumor 
cells (10, 17, 26). Elastin digests and elastin-derived peptides 
have also been shown to be chemoattractants for monocytes 
and fibroblasts (24, 25). The recent observation that elastin 
degradation products act on calcium ion channels in mono- 
cytes, fibroblasts, and smooth muscle cells provides addi- 
tional evidence for phenotypic modulation by elastin (11). 
VGVAPG is a hexapeptide that is repeated multiple times 
in the elastin molecule (22).  This elastin sequence is active 
as a chemoattractant for monocytes and for elastin-producing 
fibroblasts (25).  Although VGVAPG represents a potentially 
important class of matrix-derived chemotactic molecules, 
little is known concerning its mechanism of action. Because 
tumor cells can adhere to elastin (17) and degrade elastin to 
small peptides (13, 14), we have inquired whether VGVAPG 
can stimulate tumor cell migration. Our results demonstrate 
that VGVAPG is chemotactic for certain tumor cell lines such 
as the M27 line of the Lewis lung carcinoma. Using a radio- 
labeled tyrosinated analog (Y-VGVAPG), we then studied the 
binding of this ligand to molecules on the M27 cell surface. 
Joachim Sasses present address is Shriner's Hospital, Tampa, FL 33612. 
Scatchard  analysis of binding  and  covalent cross-linking 
experiments indicate that the primary binding site for the 
elastin-derived chemotactic peptide is an 59,000-Mr species 
on the tumor cell surface. 
Materials and Methods 
Cell Culture 
The M27 clone of murine Lewis lung carcinoma was selected in vivo from 
a metastatic tumor cell colony found in a  mouse lung after subcutaneous 
inoculation of the parental 3LL Lewis lung carcinoma tumor (3). The cells 
were cultured as previously described (3). To ensure maintenance of the in- 
vasive metastatic phenotype, cells were periodically reisolated from lung 
metastases formed subsequent to subcutaneous injection of 5  ×  105 cells 
in C57BL/6 mice. All studies were performed on cells that had been subcul- 
tured <10 times in vitro. 
Chemoattractants 
Synthetic peptides VGVAPG and Y-VGVAPG were prepared by solid phase 
methods (16, 21) using an automated peptide synthesizer (model 430A; Ap- 
plied Biosystems  Inc., Foster City, CA). Purity oftbe synthetic peptides was 
analyzed by reversed phase chromatography on a C8 column (Rainin Instru- 
ments, Woburn, MA) and was found to exceed 95 % in each case. 
Migration Assays 
Cell migration was evaluated by a modification of the method of Boyden (2), 
using a 48-multiwell chemotaxis chamber (Neuro Probe, Inc., Cabin John, 
MD). Dilutions of the peptide to be tested were placed in lower compart- 
ments of the chamber and covered with an 8-p.m porosity, 25  ×  80 mm 
polycarbonate membrane filter (Nucleopore Corp., Pleasanton, CA), which 
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fibronectin (Cooper Biomedical, Inc.,  Malvern, PA)  to increase cellular 
adhesion to the filter.  Fibronectin was determined in control experiments 
to be superior to laminin or type IV collagen as a substratum for adhesion 
and migration of the M27 tumor cells. Cells to be assayed were detached 
from culture vessels using a solution of 0.05 % trypsin-0.53 mM EDTA and 
the trypsin was subsequently inactivated by addition of medium containing 
5% FBS. The cells were washed and suspended in serum-free medium for 
the migration assay. Aliquots of 50 lal, containing ,x,5,000 cells were placed 
in the upper wells of the chamber, and the entire apparatus was incubated 
at 37°C for 3 h. After incubation, cells adhering to the upper surface of the 
filter were removed by scraping with a  rubber spatula; cells that had mi- 
grated to the lower surface were fixed in neutral-buffered 10% formalin fol- 
lowed by overnight staining with 1% nuclear fast red. The filter was then 
rinsed and mounted between two glass slides with 90%  glycerol in PBS. 
The total  number of cells that had migrated across the filter in each micro- 
well was counted at 100x under bright-field illumination. Chemotactic re- 
sponse was defined as the number of cells which traversed the filter in re- 
sponse to the peptide minus the number of cells migrating in the absence 
of peptide. 
Preparation of  Radiolabeled Peptide 
To  allow  iodination  of the elastin-derived peptide,  VGVAPG,  a  related 
peptide  was  synthesized that  contained  tyrosine  at  the  amino terminus 
(Y-VGVAPG). Iodination of Y-VGVAPG was performed using chloramine-T 
according to the method of Greenwood et al. (7). The reaction product was 
applied  to  a  5-ml column of DEAE-Sephadex A-25 ion exchange resin 
equilibrated  with  0.01  N  ammonium  acetate,  pH  8.5.  Radiolabeled 
Y-VGVAPG was eluted with 0.6 N ammonium acetate, pH 8.5, and the pH 
of peak fractions was neutralized. 
[JzsI]Y-VGVAPG was further purified before use in binding assays by 
reversed-phase HPLC in order to ensure removal of free iodine and iodi- 
nated tyrosine.  The radioiodinated peptide was diluted  1-10 in 0.1%  tri- 
fluoroacetic acid (TFA) j and the sample was then applied to a Vydac C18 
HPLC column (Rainin Instrument Co., Inc., Woburn, MA) equilibrated in 
0.1% TFA. The column was washed for 10 min with equilibration buffer at 
a flow rate of 1 ml/min and radioactivity was then eluted with a linear gra- 
dient to 90% acetonitrile, 0.1% TFA formed over a 30-rain period at 1 ml/ 
min. Approximately 88 % of the radioactivity applied to the column eluted 
with 36% acetonitrile, conditions which elute unlabeled Y-VGVAPG. This 
material was stored at  -20°C and subsequently used for binding assays. 
Calculation of specific activity (110 Ci/mmol) was based on the amount of 
radioactivity in the recovered radiolabeled peptide and its optical density 
at 280 nm. Approximately 70% of the peptide added to the chloramine-T 
iodination reaction was recovered after HPLC purification. 
Measurement of  Peptide Binding 
Because M27 cells are easily detached from culture dishes, binding assays 
were performed on cell suspensions to minimize cell loss during washing 
steps. Initial binding experiments determined that cells disrupted with tryp- 
sin-EDTA bound [125I]Y-VGVAPG equally well as did cells disrupted with 
EDTA alone. M2"/cells were subsequently prepared for binding assays with 
trypsin-EDTA solution and  suspended in  Hank's balanced  salt solution 
(HBSS) buffered with Hepes preequilibrated to 37 or 4°C. As shown in Table 
I, binding at 4°C showed a relatively narrow pH optimum between pH 6.5 
and 7.0. Subsequent experiments were performed at pH 6.8. 
M27 tumor cells were suspended in binding buffer at a cell density of 
250,000 cells/ml. The binding reaction was initiated by addition of 1.0 ml 
cell suspension to 10 ~1 [~25I]Y-VGVAPG in microcentrifuge tubes. To con- 
trol for nonspecific binding, parallel reaction tubes were incubated in the 
presence of 100- to 1,000-fold  excess unlabeled nontyrosinated VGVAPG. 
Reaction tubes were incubated with rocking at the indicated temperature. 
Binding was terminated by centrifugation at 4,000 rpm for 10 s in an Eppen- 
doff microfuge and washed rapidly with fresh binding buffer at 37 or 4°C. 
The tips of microcentrifuge tubes containing the cell pellets were snipped 
and transferred to counting tubes. The termination steps were completed in 
1.0-1.5 rain by this method, depending on the number of tubes in each experi- 
ment. [~25I]Y-VGVAPG  associated with the cells was determined in a gam- 
ma spectrometer (model 8000; Beckman Instruments, Inc., Fullerton, CA). 
Specific binding was calculated as the difference between the amount of 
1.  Abbreviations used in this paper:  DSS, disuccinimidyl suberate; TFA, 
trifluoroacetic acid. 
Table I. Effect of  pH on [12sl]Y-VGVAPG  Binding 
pH  Specific  binding* 
cpm 
5.5  1,227  +  502 
6.0  2,468  +  801 
6.5  4,344  +  552 
7.0  3,267  +  722 
7.5  1,106  +  401 
8.0  227  +  163 
8.5  20  +  28 
[a251]Y-VGVAPG (300,000 cpm/ml) was incubated at 4°C with 106 cells in the 
presence or absence of 10  -6 M unlabeled VGVAPG in Hepes-buffered HBSS 
at the indicated  pH. 
* Values are mean +  SD of triplicate  determinations. 
[~25I]Y-VGVAPG bound in the absence (total  binding) and presence (non- 
saturable binding) of unlabeled VGVAPG. 
Chemical Cross-linking 
Radioiodinalr..d  elastin peptide  was covalently bound to  M27 cells using 
a  modification  of the method of Friesel  et  al.  (5).  Binding  of [t25I]Y- 
VGVAPG to M27 cells was carried out as described above. After washing, 
the cells were incubated at 4°C in 1 ml HBSS, pH 6.8, containing 0.2 mM 
disuccinimidyl suberate (DSS; Pierce Chemical Co., Rockford, IL). DSS 
solution was prepared  as a  20 mM stock in DMSO immediately before 
cross-linking. After 20 min, the reaction was terminated by addition of 20 
I.tl of 2.0 M  Tris-HCl, pH 8.0. Cells were washed once with buffer and 
resuspended in 25-50 p,l of extraction buffer (50 mM "Iris, pH 7.3, contain- 
ing 1 mM EDTA, 0.1 mM phenylmethylsnlfonyl fluoride, 200 mM NaCI, 
1.0% [wt/vol] Triton X-100).  Cells were incubated in the extraction buffer 
at 4°C for 30 min. Insoluble material was removed by centrifugation at 
15,000 g  for 5  min at 4°C.  The supernatant was collected for immediate 
analysis or was frozen at  -70°C. 
Electrophoresis 
SDS-PAGE was performed as described by Laemmli (15).  Samples were 
heated to  100°C for 2  rain in SDS-sample buffer and subjected to elec- 
trophoresis on 10% acrylamide slab gels using a Protean minigel apparatus 
(Bio-Rad Laboratories, Richmond, CA). After electrophoresis, gels were 
stained with 0.05 % Coomassie Blue dye and subjected to autoradiography 
at  -70°C  for  1-5  d  using XAR film (Eastman Kodak Co.,  Rochester, 
NY)  and  Lighting Plus intensifying screens (Dupont  Co.,  Wilmington, 
DE). Relative intensities of bands on autoradiograms were quantified using 
a scanning densitometer (model GS 300; Hoefer Scientific Instruments, San 
Francisco, CA). 
Size-exclusion Chromatography 
Chromatography  was  performed  on  a  Bio-Rad  Laboratories  TSK-250 
column (300  ×  7.5  mm) equilibrated with 0.2 M  phosphate buffer con- 
raining 0.1  M  NaCI, 5%  methanol, and 0.1%  SDS (Buffer A). Detergent- 
solubilized cross-linked material in Buffer A was applied to the column and 
eluted with Buffer A at a flow rate of 1 ml/min. Fractions of 0.5 ml were 
collected and radioactivity in each fraction was counted. Standard proteins 
prepared in buffer A were chromatographed and their elution volumes were 
determined by OD at 280 nm. The molecular size of the receptor/ligand com- 
plex was estimated by interpolation using a  standard curve prepared with 
the following proteins:  thyroglobulin, Mr 670,000;  gamma globulin,  Mr 
158,000;  BSA, Mr 67000; ovalbumin, Mr 44,000;  myoglobin, M,  17,000; 
and vitamin B-12, Mr  1,350. 
Results 
Chemotactic Response to VGVAPG 
The  repeating  elastin  hexapeptide,  VGVAPG,  which  has 
been shown to possess chemotactic activity for monocytes 
and elastin-producing fibroblasts (25), was synthesized and 
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Figure 1.  M27  tumor cell  migration  in  response  to an elastin- 
derived peptide. The indicated concentrations of synthetic hexapep- 
tide  VGVAPG were placed  in lower wells and  5,000 cells  were 
placed  in the upper wells of chemotaxis chambers.  Data are ex- 
pressed as the number of tumor cells/well that had migrated across 
the filter during a 3-h incubation period  (mean  +  SD, n >  12). 
tested for chemotactic activity on an invasive, metastatic tu- 
mor  cell  line  (Lewis  lung  carcinoma;  line  M27).  When 
placed in the lower wells of a Boyden multiwell chemotaxis 
chamber, VGVAPG stimulated cell migration across the mi- 
cropore filter at concentrations  between  10  -9 and  10  -8 M 
(Fig.  1).  The concentration of VGVAPG required  to elicit 
half-maximal  activity  was  "~3  x  10  -9  M.  The  optimal 
VGVAPG dose for stimulation of directional M27 cell migra- 
tion is in the same concentration range as the effective dose 
reported  for  monocytes  and  elastin-producing  fibroblasts 
(25).  A chemotactic response to the elastin-derived peptide 
is not a property of all tumor cells but it is not unique to the 
M27  Lewis lung  carcinoma cells.  B16  melanoma variants 
were also chemotactic for VGVAPG although the magnitude 
of the B16 response was less than that of M27 tumor cells 
(data not shown). 
Several  mammalian  cell  chemoattractants  have  been 
shown to bind to specific cell surface receptors on their target 
cell surfaces (1, 8, 19, 30). We therefore investigated whether 
the elastin  hexapeptide,  VGVAPG, might bind  to a  corre- 
sponding receptor on M27 tumor cells.  To facilitate radio- 
labeling of the peptide for receptor binding studies,  a sec- 
ond peptide was synthesized with a tyrosine residue attached 
to the amino terminus (Y-VGVAPG). The biological activities 
of the tyrosinated peptide analog before and after iodination 
were evaluated using the migration assay. As shown in Table 
II, the effective doses of VGVAPG, Y-VGVAPG, and [~25I]Y- 
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Figure 2.  Time course  of specific binding of [125I]Y-VGVAPG to 
M27 cells at different temperatures. Tumor cells (250,000 cells/ml) 
were incubated with 1 ng [~25I]Y-VGVAPG  in the presence or ab- 
sence of excess unlabeled VGVAPG at 37 (o) or 4°C (o). Cell- 
associated radioactivity was determined at the indicated times. Each 
point shows the mean specific binding +  SD observed in duplicate 
tubes in two independent experiments. 
VGVAPG for stimulation of M27 cell chemotaxis were com- 
parable to each other. 
F25]Y-VGVAPG Binding to M27 Tumor Cells 
The binding of [~25I]Y-VGVAPG by viable M27 tumor cells 
was specific, saturable, and of high affinity.  Binding of the 
radiolabeled peptide to M27 cells was effectively inhibited by 
excess concentrations of unlabeled VGVAPG, indicating that 
both tyrosinated and nontyrosinated ligands competitively in- 
teract with the same class of binding sites.  [~25I]Y-VGVAPG 
binding was fully inhibited by pancreatic elastase digests of 
insoluble elastin,  but was not blocked by the chemotactic 
peptides fMLP and C5a (data not shown). 
A time course of specific binding at two incubation tem- 
peratures is shown in Fig. 2. At 4°C, steady state binding was 
reached by 60 min and maintained through 180 min. Binding 
of [~2~I]Y-VGVAPG at 37°C reached a maximal level by 60 
min, but longer incubation times resulted in decreased spe- 
cific binding. Decreases in cell-associated radioactivity after 
prolonged incubation at 37°C are frequently encountered in 
radioligand  binding  assays of biologically  active peptides 
and are thought to result from internalization and degrada- 
tion of the receptor/ligand complex (4). To test for internali- 
zation of [t25I]Y-VGVAPG  at 37°C,  the sensitivity of cell-as- 
sociated radioactivity to removal by trypsin was determined. 
Fig.  3 shows that radiolabeled peptide bound to M27 cells 
rapidly became trypsin-insensitive,  suggesting that the re- 
ceptor/ligand complex was being internalized.  Parallel ex- 
periments performed at 4°C resulted in trypsin sensitivity of 
70-80 % bound radioactivity (data not shown). Comparative 
reversed phase HPLC analysis of unbound radioactivity after 
Table II. Chemotactic Activity of VGVAPG Analogs Modified at the Amino Terminus 
Peptide  Chemotactic response* 
10  -9 M  5  X  10  -9 M  10  -s M  10  -r M 
VGVAPG  109  +  25  968  +  150  454  +  75  290  +  28 
Y-VGVAPG  135  +  26  832  +  94  412  +  55  347  +  15 
[125I]Y-VGVAPG  159  +  17  777  +  58  429  +  59  348  +  81 
* Mean number of M27 cells/well  migrating in response to peptide  +  SD, n  >/ 8. 
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Figure 3. Internalization of bound [125I]Y-VGVAPG  by M27 cells. 
Cells were incubated with 1 ng/ml [~25I]Y-VGVAPG  for 45 min at 
37°C.  Binding  was terminated  by removal of unbound  peptide, 
washing,  and resuspension of cells in 1 ml fresh binding buffer at 
37°C. At the indicated times, cells were treated with trypsin for l0 
min at 25°C  and  rapidly pelleted  at  13,000 g  in  an Eppendorf 
microfuge. Radioactivity in the supernatant (open bars, trypsin- 
sensitive)  and associated with cell pellet (hatched bars, trypsin- 
insensitive)  was determined. 
45 and 120 min at 37°C revealed significant extrusion ofiodi- 
nated degradation products into the medium at 120 min (Fig. 
4, b and c). The integrity of unbound radiolabeled ligand was 
remarkably stable during binding assays performed at 4°C, 
even after prolonged 2-h incubation periods (Fig. 4 a). There- 
fore, at 37°C receptor-bound ligand appears to be degraded 
by M27 cells subsequent to transformation to a trypsin-insen- 
sitive form. This process was inhibited during binding assays 
performed at 4°C. 
The rates of release of cell-associated radioactivity after 
binding at 37 and 4°C are compared in Fig. 5. The half-time 
for release of radiolabeled  ligand at 4°C,  a  temperature at 
which receptor-mediated endocytosis is inhibited,  was short 
(t,~  =  11  min) and followed first order kinetics.  Release of 
radioactivity from M27 ceils at 37°C  was prolonged  (t,~ = 
55 min), a result which is consistent with the ligand internal- 
ization demonstrated in Fig. 3. The off-rate at 37°C is, there- 
fore,  more  representative  of  the  rate  at  which  the  cells 
extrude degraded ligand,  while the off-rate at 4°C more ac- 
curately defines the ligand/receptor  interaction. 
The concentration  dependence  of [~25I]Y-VGVAPG bind- 
ing to M27 cells over 45  min at both 4  and  37°C  is shown 
in  Fig.  6  A.  Specific binding  of VGVAPG to M27  cells  is 
saturable at concentrations in excess of 5 ng/ml. Under these 
conditions, nonspecific binding at 37°C was 30-45 % of total 
bound radioactivity. Nonspecific binding at 4°C was higher, 
ranging from 40-60%  of total bound radioactivity.  Equiva- 
lent quantities  of [125I]Y-VGVAPG were  specifically bound 
by M27 cells at each temperature, indicating the same num- 
ber of available binding  sites. 
Scatchard analysis (Fig. 6 B) of the binding data presented 
in Fig.  6 A  revealed that the ratio of bound vs. bound/free 
labeled peptide was a  linear function  (r  =  0.98  at 37°C;  r 
=  0.99 at 4°C),  indicating  a  single class of noninteracting 
binding sites in this concentration range (23).  [~25I]Y~VGVAPG 
binds to M27 cells with high affinity (Kd  =  2.7  nM) as de- 
termined from the slope of the plot.  After 45 min exposure 
to  ['25I]Y-VGVAPG, each  cell had  a  maximum binding  ca- 
pacity of 52,000 ligand molecules. Analysis is based on bind- 
ing data from multiple experiments (n  =  6  at 37°C;  n  =  4 
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Figure 4. Reversed phase chromatography of unbound radiolabeled 
ligand at 4 and 37°C during binding assays.  [~25I]Y-VGVAPG  bind- 
ing to M27 cells was allowed  to proceed at (a) 4°C for 120 min, 
(b) 37°C for 45 min, and (c) 37°C  for 120 min. Cells were cen- 
trifuged and supernatants were immediately applied to a C18 Vydac 
HPLC  column equilibrated  with 0.1% TFA.  Bars, radioactivity 
present in each fraction eluted with a gradient of 0-80% Buffer B 
(0.1% TFA in 90%  acetonitrile) generated over a 30-min period. 
95-100% of radioactivity from parallel tubes incubated in the ab- 
sence of cells at either temperature eluted in fraction 17. 
at 4°C). These results firmly establish the existence of a high 
affinity binding  site for VGVAPG on M27 cells that has the 
properties of a  specific receptor. 
Cross-linking of pq]Y-VGVAPG to the Cell Surface 
M27 carcinoma cells contain a single membrane component 
that can be specifically cross-linked to [~25I]Y-VGVAPG with 
200 ~tM DSS. The [~25I]Y-VGVAPG cross-linked species has 
an Mr of 59,000,  as determined by SDS-PAGE (Fig.  7). In- 
corporation of label into this species was not observed using 
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Figure 5. Rates of dissociation 
of [t25I]Y-VGVttPG  bound by 
M27 cells at different temper- 
atures.  Cells  were  incubated 
with 1 ng/ml [125I]Y-VGVAPG 
for 45 min at 37 (e) or 4°C 
(o),  washed  free of unbound 
peptide,  and then resuspended 
in  fresh  binding  buffer  pre- 
equilibrated  to the appropriate 
temperature.  At the indicated 
times,  cell-associated  radio- 
activity was  determined.  Re- 
sults are the means of triplicate 
determinations. 
M27 cells that were incubated with the radioligand in the ab- 
sence of DSS.  Radiolabeling of the Mr 59,000 species  was 
effectively competed in a concentration-dependent manner by 
excess unlabeled VGVAPG. Densitometric  scans of the au- 
toradiographic bands demonstrate inhibition of receptor la- 
beling by excess unlabeled VGVAPG (Table III). The electro- 
phoretic mobility of the cross-linked species was not altered 
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Figure 6. Concentration dependence of [t25I]Y-VGVAPG  binding to 
M27 cells.  Tumor cells  (250,000 cells/ml)  were incubated  for 45 
min at either 37 (e) or 4°C (o) with the indicated  concentrations 
of [~2~I]Y-VGVAPG  in the presence or absence of excess unlabeled 
VGVAPG. (A) Each point represents  the mean specific binding of 
radiolabeled  peptide  (SD ~< 10%, n  =  4). (B) The ratio of [t25I]Y- 
VGVAPG specifically  bound to unbound peptide  was calculated 
from the binding data shown in Fig.  6 A and plotted as a function 
of specific binding. 
Table IlL Specific Incorporation  of [1251]Y-VGVAPG into 
Mr 59,000 species 
VGVAPG Added  %  Inhibition 
tzM 
0  0 
2  86 
10  98 
50  100 
by the addition  of the  reducing agent,  2-mercaptoethanol, 
suggesting that the M27 tumor cell surface VGVAPG-binding 
protein is monomeric.  Occasionally minor bands appeared 
at Mr 49,000, 37,000,  and 33,000. Since detergent extracts of 
whole M27 cells were used for these studies, the minor bands 
may represent receptor molecules that were modified during 
internalization  of the ligand/receptor complex. 
[125I]Y-VGVAPG binding to M27 cells at 4°C rather than 
37°C before addition of  the cross-linking agent resulted in the 
incorporation  of radiolabel  into only the  59,000-Mr  mole- 
cule, as determined by size-exclusion chromatography (Fig. 
8). An estimate of the molecular size of the cross-linked spe- 
cies was obtained by comparison to elution volumes of stan- 
dards with known molecular sizes in a parallel run. For this 
analysis addition  of detergent  to the  mobile phase was re- 
quired to inhibit interaction of the radioactive ligand/receptor 
complex with the TSK column. The single peak of radioac- 
tivity at •59,000  Mr was not observed for cells in which ex- 
cess unlabeled VGVAPG was added to the binding reaction. 
Discussion 
The  extracellular  matrix  protein  elastin  contains  domains 
that modulate cellular behavior (10,  11, 17, 24, 26). We now 
demonstrate the ability of Lewis lung carcinoma cells (line 
M27), an invasive and metastatic tumor cell line, to respond 
chemotactically to VGVAPG, an  elastin-derived  repeat  se- 
quence. M27 cells detect soluble VGVAPG by binding of the 
chemotaxin to a  specific high affinity cell surface receptor, 
which we have identified as a protein with an Mr of 59,000. 
We postulate that VGVAPG binding to its receptor initiates 
intracellular processes that result in the M27 tumor cell mi- 
gratory response. 
Figure  7.  Cross-linking  of 
[12sI]Y-VGVAPG  to M27 cells 
and  analysis  of  the  cross- 
linked  complex  by  SDS- 
PAGE. M27 tumor cells (5  × 
105  )  were  incubated  in  the 
presence  of 5  ng/ml  [125I]Y- 
VGVAPG alone or with vari- 
ous  concentrations  of  unla- 
beled VGVAPG. At the end of 
the  incubation,  cells  were 
rapidly  washed,  cross-linked 
with DSS, and processed for electrophoresis.  The resulting autora- 
diogram of  a 10% (wt/vol) SDS-PAGE gel is shown. Lane 1, 0 ttM 
VGVAPG; lane 2, 2 ttM VGVAPG; lane 3,  10 I.tM VGVAPG; lane 
4, 50 ttM VGVAPG; and lane 5,  100 ttM VGVAPG. 
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Figure 8. Size exclusion chromatography  of cross-linked M27 cell 
extracts, p25I]Y-VGVAPG was bound to M27 cells  at 4°C for 45 
min and cross-linked to the cell surface with 200 gM DSS. Deter- 
gent extracts of M27 cells were immediately fractionated on a TSK- 
250 column preequilibrated with Buffer A. Bars, the radioactivity 
present in each fraction. 
Radioligand binding assays and subsequent Scatchard anal- 
ysis  of  specific  peptide  binding  detected  the presence  of 
one class of high affinity binding molecules on the surface 
of M27 tumor cells. The affinity constant of this receptor was 
calculated  to  be  2.7  ×  10  -9  M,  which  correlates  closely 
with the concentration range required to elicit a chemotactic 
response by these cells. Receptors on M27 cells bound p2sI]Y- 
VGVAPG with similar kinetics at 4 and 37°C. These results 
indicate that M27 cells present receptor at the cell  surface 
without the requirement for mobilization of receptor to the 
membrane  in response  to initial  receptor  occupancy.  The 
difference  in  off-rates  between  the two  temperatures  is  a 
reflection of uptake of the ligand at 37°C, as is evidenced by 
internalization data. This disparity in ligand off-rates has also 
been encountered with receptor binding to the chemotactic 
peptide f-MLP (12, 29,  30). 
Several other cell surface molecules have been identified 
which interact with the elastin molecule (9, 10). Using elas- 
tin-affinity chromatography Hornebeck et al. (10) identified 
a  120,000 Mr protein on the surface of mesenchymal cells, 
which was termed "elastonectin" This protein was shown to 
mediate cellular adhesion to insoluble elastin.  A  67-kD re- 
ceptor for tropoelastin has been described (28) and identified 
(9),  which is thought to be involved in assembly of elastin 
fibers from the tropoelastin precursor. Elastin-affinity chro- 
matography on detergent-solubilized M27 cell membrane pro- 
teins resulted in VGVAPG  elution of proteins migrating on 
electrophoresis as major bands with Mrs of 67,000,  60,000, 
and 47,000.  However,  at VGVAPG  concentrations used for 
binding studies and covalent cross-linking, only the 59,000- 
Mr protein was detected. It is not presently known whether 
this 59,000-Mr protein exhibits considerably higher affinity 
for VGVAPG than other potential elastin-binding proteins on 
the M27 cell surface or whether only the 59,000-Mr protein 
binds the iodinated, tyrosinated agonist. Alternatively, this 
receptor may be unoccupied, whereas other elastin receptors 
may be occupied on M27 cells. 
Since only one class of binding protein for VGVAPG was 
detected on M27 carcinoma cells by Scatchard analysis, we 
postulate  that  the  59,000-Mr  species  identified  by  cross- 
linking is likely to be critical to the chemotactic response of 
M27 tumor cells.  Chemotaxis of leukocytic cells has been 
shown to involve guanine nucleotide binding proteins (18, 27) 
and intracellular calcium mobilization (27). It will therefore 
be of interest to determine whether VGVAPG binding to the 
59,000-Mr receptor initiates a similar sequence of intracel- 
lular events. Elastin peptides modulate calcium ion fluxes in 
monocytes, fibroblasts, and smooth muscle cells (11), which 
also migrate in response to VGVAPG (25). It is not presently 
known whether the 59,000-M, receptor for VGVAPG  is ex- 
pressed  on  these  cell  types.  The  requirement  of a  high 
affinity 59,000-Mr VGVAPG  receptor for chemotaxis to the 
peptide is presently being evaluated on responsive and non- 
responsive cell types. 
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